Would you consider using ruxolitinib instead of TCS with a patient on dupilumab for breakthrough flares?
Featuring Peter Lio, MD | Clinical Assistant Professor of DermatologyNorthwestern University Feinberg School of MedicineChicago, IL | Published December 22, 2022
Related Media
Powered by Polaris TM